Author:
Nourah Hassan Alzahrani,Fareed Shawky El-Shenawy
Abstract
Six clinical Staphylococcus aureus strains isolated from different clinical samples. Isolates ASIA1 and ASIA2 isolated from urine samples of urinary tract infected patients; ASIA3 isolated from swab samples of burn abscess patients at Assiut University hospital as well as ASIA4, ASIA5 and ASIA6 obtained from blood samples of different cancer patients at South Egypt Cancer Institute. All isolates showed varied abilities to produce halo zones of hydrolysis with different diameters on blood agar, heated plasma agar, casein agar and skim milk agar plates along with different clot lyses percent. Staphylococcus aureus ASIA3, ASIA4 and ASIA6 produced 4.83, 5.98 and 2.08 U/mL of staphylokinase on tryptone soy broth reduced to 1.95, 2.08 and 1.70 U/mL on casein hydrolysate yeast extract broth, respectively. On the other hand, Staphylococcus aureus ASIA1, ASIA2 and ASIA5 gave 2.20, 2.93 and 3.65 U/mL on CYEB compared to 2.10, 1.88 and 3.41 U/mL on TSB as production medium. The staphylokinase yielded from the hyperactive producer Staphylococcus aureus ASIA4 was increased for 7.64-fold (from 2.08 U/mL to 15.88 U/mL) on the optimized fermentation medium composed of 5.0 g sucrose as carbon source, 10.0 g soy bean as nitrogen source, 5.0 g NaCl, K2HPO4 5.0 g and pH 7.0 that inoculated with isolate ASIA4 and incubated for 24 h at 35 °C. Moreover, Staphylokinase activity reached its peak at the optimal enzymatic reaction conditions which were reaction time 25 min, casein as substrate, reaction pH 8.0, reaction temperature 40 °C. In addition it retained 100% of its activity at temperature ranged between 15 and 45 °C and pH ranged from pH 6.0 to 9.0. EDTA inhibited the enzyme activity by 3.0% to 32.2% with increasing its values from 30.0 to 90.0 mM. MgCl2 at a concentration of 30 mM increased the enzyme activity by 4% and then slightly decreased at higher concentrations but NaCl was potent staphylokinase activator at concentrations lower than 90 mM.
Publisher
Heighten Science Publications Corporation
Reference32 articles.
1. 1. Min W, Yao C, Wenliang F, Minji Z, Yuanyuan W,et al. Construction of a novel staphylokinase (SAK) mutant with low immunogenicity and its evaluation in rhesus monkey. Int J Biol Macromol. 2020; 146: 781-789. https://pubmed.ncbi.nlm.nih.gov/31730959/
2. 2. Nedaeinia R, Faraji H, Javanmard SH, et al. Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion. Mol Biol Rep. 2020; 47: 819-841. https://pubmed.ncbi.nlm.nih.gov/31677034/
3. 3. Shah NR, Panchal HK. Screening of staphylokinase producing Staphylococcus spp. from different sources. GJBB. 2019; 8: 194-197.
4. Screening and optimization of staphylokinase from Staphylococcus aureus isolated from nasal swab of healthy students in Himachal Pradesh University, India;Deepa;Biomed Biotechnol Res J,2019
5. 5. Jasim HM, Dellol RA, Hamzah AS. Optimum conditions of staphylokinase production cloned in E. coli Jm109 (De3). Int J Curr Microbiol Appl Sci. 2015; 4: 10-19.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献